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Introduction: The CRASH-2 trial demonstrated that tranexamic acid (TXA) reduced mortality with 
no increase in adverse events in severely injured adults. TXA has since been widely used in injured 
adults worldwide. Our objective was to estimate mortality and adverse events in adults with trauma 
receiving TXA in studies published after the CRASH-2 trial. 
Methods: We systematically searched PubMed, Embase, MicroMedex, and ClinicalTrials.gov for 
studies that included injured adults who received TXA and reported mortality and/or adverse events. 
Two reviewers independently assessed study eligibility, abstracted data, and assessed the risk 
of bias. We conducted meta-analyses using random effects models to estimate the incidence of 
mortality at 28 or 30 days and in-hospital thrombotic events.  
Results: We included 19 studies and 13 studies in the systematic review and meta-analyses, 
respectively. The pooled incidence of mortality at 28 or 30 days (five studies, 1538 patients) was 
10.1% (95% confidence interval [CI], 7.8-12.4%) (vs 14.5% [95% CI, 13.9-15.2%] in the CRASH-2 
trial), and the pooled incidence of in-hospital thrombotic events (nine studies, 1656 patients) was 
5.9% (95% CI, 3.3-8.5%) (vs 2.0% [95% CI, 1.8-2.3%] in the CRASH-2 trial).
Conclusion: Compared to the CRASH-2 trial, adult trauma patients receiving TXA identified in our 
systematic review had a lower incidence of mortality at 28 or 30 days, but a higher incidence of in-
hospital thrombotic events. Our findings neither support nor refute the findings of the CRASH-2 trial 
but suggest that incidence rates in adults with trauma in settings outside of the CRASH-2 trial may 
be different than those observed in the CRASH-2 trial. [West J Emerg Med.2019;20(3):443–453.]
INTRODUCTION
Hemorrhage is the primary cause of death in the first 24 
hours after trauma and is responsible for 40% of all trauma-
related deaths.1,2 Tranexamic acid (TXA), an antifibrinolytic drug 
that blocks plasmin-mediated fibrin clot breakdown, attenuates 
excessive bleeding. In patients undergoing surgery, TXA has been 
shown to decrease blood product transfusion requirements.3,4 
The success of TXA in the surgical setting led to the CRASH-2 
trial, an international, randomized controlled trial of the early 
administration of TXA to bleeding adult trauma patients.5 
Universtiy of California, Davis Medical Center, Department of Emergency Medicine, 
Sacramento, California
Compared to placebo, TXA given within three hours of injury, 
reduced the risk of hemorrhagic death by approximately one-third 
with no increase in adverse events.6 
Administering TXA is now considered standard treatment in 
adults with traumatic bleeding and its use has been implemented 
worldwide.7 The use of TXA for injured adults has been estimated 
to save 112,000 lives per year worldwide.8 Given that the 
CRASH-2 trial was conducted in primarily developing countries 
where transfusion practices and identification of adverse events 
may differ compared to developed countries, we sought to 
Western Journal of Emergency Medicine 444 Volume 20, no. 3: May 2019
Mortality and Thrombosis in Injured Adults Receiving TXA in the Post-CRASH-2 Era Benipal et al.
estimate the incidence of mortality and thrombotic events in 
injured adults in the post-CRASH-2 era.9 Our objective was to 
evaluate the incidence of mortality and adverse events in studies 
published after the CRASH-2 trial results were published. 
METHODS
Search Strategy
We searched PubMed, Embase, MicroMedex, and 
ClinicalTrials.gov for studies that included adult trauma patients 
who received TXA and reported mortality and/or adverse events 
(Supplemental File). References of potentially eligible articles 
identified in the search were further screened for relevant 
references missed in the database search.
Inclusion and Exclusion
We included all studies that assessed mortality and/or 
adverse events in adult trauma patients receiving TXA. We 
included studies regardless of TXA dosing or clinical setting 
(e.g., prehospital, military, civilian) and studies that reported only 
mortality or adverse events. We excluded case reports and review 
articles, studies that were not trauma-related or that included 
primarily children, and studies that did not report mortality or 
adverse events. We also excluded studies that were secondary 
analyses of the CRASH-2 trial. 
Study Selection
We screened studies for inclusion initially by titles, 
abstracts, and then full texts. Each study title and abstract was 
reviewed independently by two authors. When consensus 
could not be reached on screened titles and abstracts, a third 
reviewer independently adjudicated the discrepancies. Full-
text discrepancies were resolved by group consensus during 
in-person meetings. Prior to independent author screening, we 
piloted the study selection procedures as a group for several 
studies to enhance standardization of the selection protocol. Our 
study selection procedure is reported for in Figure 1 according 
to the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) (See Figure 1). 
Data Abstraction and Quality Assessment
Two authors independently abstracted data from each of 
the included studies. We abstracted study characteristics that 
included the following: year, country, setting (e.g., civilian, 
military, prehospital), design, inclusion criteria, TXA dosing, 
and outcomes measured. We abstracted outcome measures 
including mortality during any time frame, thrombotic events, 
and other adverse events reported, as well as adverse event 
definitions provided by the authors of the included study. 
Extraction was piloted as a group on several studies. We 
resolved disagreements in extracted data by group discussion 
and by consensus of all authors. 
We assessed the quality of included studies using a quality 
assessment instrument previously developed by the National 
Heart, Lung, and Blood Institute.11 This instrument included 
nine points assessing the clarity of the study objective and study 
population, the sequence of enrollment (consecutive vs. non-
consecutive), the comparability of subjects, the clarity of the 
study intervention and the outcome measures, the adequacy of 
length of follow-up, the appropriateness of statistical methods, 
and the clarity of reported results. 
Outcome Measures
Our primary outcomes were mortality at 28 days and 
in-hospital thrombotic events, as these were outcomes 
reported in the CRASH-2 trial.5 We identified studies that 
reported mortality at 30 days and thus expanded this outcome 
to include mortality at both 28 and 30 days. In-hospital 
thrombotic events for the CRASH-2 trial were defined as any 
vascular occlusive event including myocardial infarction, 
stroke, pulmonary embolism (PE) and deep vein thrombosis 
(DVT). We accepted any definition of an in-hospital 
thrombotic event as reported by the included studies. Since the 
majority of the studies reported total thrombotic events rather 
than the number of patients with thrombosis, we reported on 
total number of thrombotic events (i.e., if one patient had both 
a DVT and stroke identified, it would count as two thrombotic 
events). Secondary outcomes included mortality at 24 hours, 
in-hospital mortality, and in-hospital PE or DVT. 
Analysis
Prior to pooling the data, we assessed studies for clinical 
heterogeneity based on study population, setting, design, 
intervention, and outcome assessment. All authors participated 
in group discussions to determine which studies should be 
excluded from the meta-analyses due to significant clinical 
heterogeneity compared to the other studies. We performed 
meta-analyses using the random effects model to report incidence 
with 95% confidence intervals (CI). Statistical heterogeneity was 
assessed with I2 where a value >75% represents considerable 
heterogeneity.12 Forest plots were ordered along the Y-axis by 
descending sample size.13 We did not construct a funnel plot 
to assess for publication bias as these have been shown to be 
inaccurate for assessing incidence and may cross the 0 and 100% 
boundaries.14 Statistical analysis was performed using Stata 14.0 
(College Station, Texas). 
RESULTS
Characteristics of Studies
The search strategy yielded a total of 4100 articles. After 
duplicates were removed and abstracts screened, we assessed 52 
full-text articles for eligibility. Of these full-text articles, 33 were 
excluded. Reasons for exclusion can be found in the PRISMA 
diagram (Figure 1). Table 1 shows the characteristics of these 19 
included studies. We identified 58 studies from ClinicalTrials.gov, 
10 of which met our inclusion criteria; however, all were ongoing 
or have not yet published results.15
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Records identified through 
PubMed (n=3,396)
Records identified through 
Embase (n=435)
Records identified through 
other sources (n=269)
Records after duplicates removed, screened by title (n=3,909)
Records screened by abstract (n=378)
Full-text articles assessed for eligibility (n=52) Full-text articles excluded, with reasons (n=33)
Commentary (n=1)
Data not provided (n=19)
Population overlap (n=2)
Review article (n=4)
Secondary analysis of CRASH-2 trial (n=7)
Studies included in qualitative synthesis (n=19) Studies excluded from meta-analysis, with reasons (n=6)
Hyperfibrinolysis only (n=1)
Selective injury criterion (n=2)
Survival criterion (n=3)Studies included in quantitative synthesis 
(meta-analysis) (n=13)
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram depicting selection of studies of 
articles for review. 
Six studies were conducted in military hospitals16-21 and 14 
were conducted in civilian hospitals (one study included both 
military and civilian hospitals).21-34 One study administered 
TXA in the prehospital setting.29 There were 13 retrospective 
studies,16-21,23-25,27,30,31,33 five prospective observational 
studies,22,26,28,29,32 and one randomized controlled trial.34 Ten 
studies22-26,29-32,34 reported administering TXA as given in the 
CRASH-2 trial (1 gram [g] intravenous [IV] bolus followed by 1 
g IV over eight hours); three studies16,20,21 reported giving TXA 1 
g bolus (without the maintenance dose), and six studies17-19,27,28,33 
did not report TXA dosing. Three studies17,27,34 administered 
TXA within eight hours from the time of injury (as done in 
the CRASH-2 trial), 12 studies16,18,21-26,29-32 administered TXA 
primarily within three hours from the time of injury, and four 
studies19,20,28,33 did not report the timing of TXA administration. 
We did not include six studies in the meta-analyses 
due to significant clinical heterogeneity compared to the 
other studies. Reasons for exclusion of these studies were 
as follows: only included patients with injury by firearm or 
explosive;16 only included patients with hyperfibrinolysis;24 
only included combat patients who survived 24 hours after 
injury27 or survived to receive treatment at a U.S. military 
hospital after transport from a combat hospital;18,19 or only 
included patients with traumatic brain injury.34
Main Results
We included 13 studies17,20-23,25,26,28-33 with 2536 adult trauma 
patients receiving TXA into the meta-analyses evaluating 
mortality at 28 or 30 days (five studies);17,25,29,30,33 in-hospital 
thrombosis (nine studies);17,21,25,26,29-33 mortality at 24 hours (four 
studies);17,25,29,33 in-hospital mortality (nine studies),20-23,26,28,31-33 
and PE and/or DVT (four  studies)17,21,26,29 (Tables 1 and 2).
The pooled incidence of mortality at 28 or 30 days was 
10.1% (95% CI, 7.8 to 12.4%; I2 = 42.7%) (Figure 2). This 
was lower than reported in the CRASH-2 trial, which had an 
incidence of mortality at 28 days of 14.5% (95% CI, 13.9 to 
15.2%) in patients receiving TXA. The pooled incidence of 
in-hospital thrombotic events was 5.9% (95% CI, 3.3 to 8.5%; 
I2 = 87.6%) (Figure 3). This was higher than reported in the 
CRASH-2 trial, which had an incidence of in-hospital thrombotic 
events of 2.0% (95% CI, 1.8 to 2.3%). The pooled incidences 
of the secondary outcomes of mortality at 24 hours, in-hospital 
mortality, and PE and/or DVT are reported in Figures 4 to 6. 
Our quality assessment suggested concerns regarding non-
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Study (author, year)
Mortality at 24 h, 
n (%)
Mortality at 28 or 30 d, 
n (%)
Mortality, in-hospital, 
n (%)
Crude thrombosis, 
n (%)
PE or DVT, 
n (%)
CRASH-2 collaborators, 
2010a
1,463 (14.5) 204 (2.0)c 112 (1.1)
Aedo-Martin et al., 2016 0 (0) 0 (0) 0 (0) 0 (0)
Cole et al., 2015b 30 (18.8) 16 (10)d
Fernandez et al., 2012b 42 (42)
Harvin et al., 2015 33 (34) 39 (40) 6 (6.3) 3 (3.3)j
Howard et al., 2017b 47 (5.5) 82 (9.7) 45 (5.3)e 45 (5.3)
Johnston et al., 2018 1 (0.7) 50 (34.2)f
Lewis et al., 2016 10 (3.0)
Luehr et al., 2017b 1 (1.9) 7 (13.5) 7 (13.2)f
Meizoso et al., 2018b 6 (17.1) 12 (34.3)e 12 (34.3)
Milligan et al., 2016 5 (7.7)
Moore et al., 2017b 13 (50.0)
Morrison et al., 2013b 57 (14.0)
Nadler et al., 2014b 17 (18.1) 2 (2.4)g 2 (2.4)g
Neeki et al., 2017b 5 (3.9) 8 (6.3) 2 (1.6)h 2 (1.6)h
Shiraishi et al., 2017b 25 (10.0) 3 (1.2)f
Valle et al., 2014b 46 (30.7)
Van Haren et al., 2014b 4 (14.8) 9 (33.3)f
Wafaisade et al., 2016b 15 (5.8) 36 (14.7) 38 (14.7) 4 (5.6)i
Yutthakasemunt et al., 2013 12 (10.0) 0 (0) 0 (0)
Table 2. Reported mortality and thrombotic complications of included studies.
h, hours; d, days; PE, pulmonary embolism; DVT, deep vein thrombosis; MI, myocardial infarction. 
aincluded as a reference; bincluded in the meta-analyses; cPE, DVT, MI, or stroke; dVTE, MI, or stroke; ePE or DVT; fVTE only; gout of 83 
patients; hDVT only; iout of 71 patients; jPE only.
consecutive patient enrollment (six studies)18,19,26,27,31,32 and an 
unclear description of the intervention (six studies).17-19,27,28,33 
See Supplemental File, eTable for complete quality 
assessments of the studies.
DISCUSSION
Our study demonstrated some interesting findings, 
particularly in comparison to the CRASH-2 trial. In our 
study, trauma centers demonstrated a wide variation of 
TXA administration including dosing (bolus vs bolus + 
maintenance), total bolus dose (1 g vs 2 g), and timing (within 
three hours vs eight hours from injury). The CRASH-2 trial 
administered TXA as a 1 g IV bolus infusion over 10 minutes 
and a 1 g maintenance infusion over eight hours within 
eight hours from the time of injury. The varying timing of 
TXA adminstration noted in our study is likely a result of an 
exploratory analysis that demonstrated increased benefit in 
preventing hemorrhagic death with earlier TXA administration 
given within one hour.6 The greatest benefit occurs when 
TXA is given within <1 hour from injury, diminished 
benefit if given within one to three hours from injury, and 
no benefit if given after three hours from injury.6 In contrast 
to the CRASH-2 trial, three studies primarily administered 
only a bolus dose of TXA as opposed to a bolus dose with a 
subsequent maintenance dose.16,20,21 This may contribute to 
different thrombosis and mortality rates. Current clinical trials 
are evaluating different TXA doses in injured patients.15 
Compared to the CRASH-2 trial, our pooled results 
demonstrated a lower incidence of mortality at 28 or 30 
days and a higher incidence of in-hospital thrombotic 
events. We do not conclude from our findings that the 
effectiveness and harm of TXA is different than what was 
demonstrated in the CRASH-2 trial, as our study included 
primarily observational studies. Our results instead suggest 
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Wafaisade et al., 2016
Luehr et al., 2017
Overall (95% CI)
Figure 2. Forest plot of the incidence of mortality at 28 or 30 days after tranexamic acid use in injured adults.
Study Proportion (95% CI) Weight, %
0.10 (0.08, 0.12) 36.01
0.10 (0.06, 0.14) 21.44
0.06 (0.02, 0.10)
0.14 (0.10, 0.18)
0.13 (0.04, 0.22)
0.10 (0.08, 0.12)
18.58
18.39
5.59
100.00
Mortality at 28 or 30 days
0 0.1 0.2 0.3
Figure 3. Forest plot of the incidence of in-hospital thrombotic events with tranexamic acid use in injured adults.
CI, confidence interval.
Chi-square=64.74 p<.0001; I2=87.6%.
Shiraishi et al., 2017
Howard et al., 2017
Wafaisade et al., 2016
Neeki et al., 2017
Nadler et al., 2014
Cole et al., 2015
Luehr et al., 2017
Meizoso et al., 2018
Van Haren et al., 2014
Overall (95% CI)
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100.0
In-hospital thrombotic events
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CI, confidence interval.
Chi-square=6.98 p=.137; I2=42.7%.
Study Proportion (95% CI) Weight, %
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Study Proportion (95% CI) Weight %
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20.78
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Figure 4. Forest plot of the incidence of mortality at 24 hours after tranexamic acid use in injured adults.
CI, confidence interval.
Chi-square=4.01 p=.260; I2=25.2%.
Figure 5. Forest plot of the incidence of in-hospital mortality after tranexamic acid use in injured adults.
CI, confidence interval.
Chi-square=53.35 p<.0001; I2=85.0%.
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In-hospital mortality
0 0.2 0.4 0.6
Mortality at 24 hours
0 0.05 0.1 0.15
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Figure 6. Forest plot of the incidence of pulmonary embolism and/or deep vein thrombosis after tranexamic acid use in injured adults.
CI, confidence interval. 
Chi-square=23.19 p<.0001; I2=87.1%.
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that the incidence rates observed in settings outside of the 
CRASH-2 trial might be different than what was observed 
in the CRASH-2 trial. This is particularly true for the 
incidence of thrombotic events, where our pooled results 
demonstrated a higher incidence of thrombotic events than 
what was observed in the CRASH-2 trial. The incidence 
rates reported in our included studies are likely biased 
towards under-reporting thrombotic events due to the 
high proportion of retrospective studies (more difficult 
to identify thrombotic events) and less-comprehensive 
definition of thrombotic event (often did not include 
arterial thromboses such as myocardial infarction or stroke) 
compared to the CRASH-2 trial. 
It is unclear why there are differences in thrombotic 
events seen in the CRASH-2 trial and our study. It 
is possible that the injury severity of the two study 
populations is different. We were unable to compare overall 
patient characteristics of our included studies with those 
of the CRASH-2 trial. It is also possible that sites included 
in the CRASH-2 trial screened less for thrombotic events 
compared to sites included in our study. Other large trauma 
clinical trials enrolling similarly injured populations have 
also reported higher thrombotic event rates compared to the 
CRASH-2 trial.35-37 Several ongoing trauma clinical trials 
evaluating TXA should provide additional insight into the 
incidence of thrombotic events in this population.15 
Future studies evaluating TXA use in patients with 
hemorrhagic injuries may consider work to identify patients 
where the potential efficacy of TXA use is maximized and 
exposure to harm is minimized. Identification may be based 
on clinical characteristics, transport time or modality, or 
laboratory measurements such as thromboelastography.38,39 
LIMITATIONS
Our results should be interpreted in the context of some 
limitations. First, the included studies demonstrated clinical 
heterogeneity, limiting the numbers of studies that could be 
included in the meta-analyses. Second, studies had varying 
definitions of in-hospital thrombosis, which may lead to 
differences in reported incidence rates. Third, the majority 
of the studies were retrospective, and this may result in less 
accurate data abstraction compared to prospective studies.40 
This limitation is more relevant for the thrombosis 
outcome measure, which may be difficult to ascertain from 
retrospective chart review, than for the mortality outcome 
measure, which is easy to ascertain regardless of study 
design. Fourth, the chart abstractors were not blinded to 
the study hypotheses. This may have led to biases during 
study selection and data abstraction. Finally, the incidence 
of thrombotic events is ideally measured with the number 
of patients with any thrombotic event as the numerator and 
the total number of patients as the denominator. However, 
since included studies primarily reported total number of 
thrombotic events, we used the total number of thrombotic 
events as the numerator and the total number of patients as 
the denominator for calculating incidence. 
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CONCLUSION
Compared to the CRASH-2 trial, adult trauma patients 
receiving TXA identified in our systematic review had a lower 
incidence of mortality at 28 or 30 days, but a higher incidence 
of in-hospital thrombotic events. Our findings neither support 
nor refute the findings of the CRASH-2 trial. They merely 
suggest that incidence rates observed in settings outside of the 
CRASH-2 trial may be different than those observed in the 
CRASH-2 trial.
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